Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
Background: The evidence regarding triple oral combination therapy for patients with pulmonary arterial hypertension (PAH) is scarce. This study was performed to investigate the effectiveness and safety of triple oral combination therapy with macitentan, riociguat, and selexipag. Methods: Among cons...
Main Authors: | Mizuki Momoi, Takahiro Hiraide, Yoshiki Shinya, Hiromi Momota, Shogo Fukui, Michiyuki Kawakami, Yuji Itabashi, Keiichi Fukuda, Masaharu Kataoka |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-02-01
|
Series: | Therapeutic Advances in Respiratory Disease |
Online Access: | https://doi.org/10.1177/1753466621995048 |
Similar Items
-
Riociguat, a soluble guanylate cyclase stimulator, ameliorates right ventricular contraction in pulmonary arterial hypertension
by: Mitsushige Murata, et al.
Published: (2017-12-01) -
Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension
by: Roxana Sulica, et al.
Published: (2019-02-01) -
Selexipag in the management of pulmonary arterial hypertension: an update
by: Coghlan JG, et al.
Published: (2019-08-01) -
Nanosuspensions of Selexipag: Formulation, Characterization, and in vitro Evaluation
by: Rusul M. Alwan, et al.
Published: (2021-06-01) -
Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension
by: Abraham Rothman, et al.
Published: (2020-02-01)